Company intelligence / Profile preview
Temple OrthoBiologics
New York, New York, United Statestempleorthobio.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
TX-33 has shown promising results in preventing fibrosis in abdominal and pelvic surgeries and is being developed for orthopedic applications, particularly for knee injuries and surgeries. It's currently on track for human trials in knees as part of the FDA approval process in late 2025 or early 2026[3].
- Therapeutic areas
- OtherRheumatology
- Modalities
- Pharmaceutical-grade compoundadvanced biomaterialstargeted drug delivery
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Partnerships across USA, Netherlands, UK, and Canada
Beyond the preview
Go deeper on Temple OrthoBiologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Temple OrthoBiologics.